复方阿嗪米特联合莫沙必利治疗老年消化不良患者的有效性及安全性  

Efficacy and safety of compound azintamide combined with mosapride in the treatment of elderly patients with dyspepsia

作　　者：曹红梅 张霞[1] CAO Hongmei;ZHANG Xia(Sun Si Miao Hospital of BUCM,Tongchuan 727100,China)

机构地区：[1]北京中医药大学孙思邈医院,陕西铜川727100

出　　处：《临床医学研究与实践》2023年第26期29-32,共4页Clinical Research and Practice

摘　　要：目的探讨复方阿嗪米特联合莫沙必利治疗老年消化不良患者的有效性及安全性。方法选择2020年1月至12月收治的96例老年消化不良患者作为研究对象,采用随机数字表法将其分为对照组和观察组,各48例。对照组给予莫沙必利治疗,观察组在对照组基础上给予复方阿嗪米特治疗。比较两组的治疗效果。结果治疗后,两组的恶心呕吐、食欲不振、反酸嗳气、腹痛腹胀积分及总积分均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组的治疗总有效率为97.92%,高于对照组的83.33%,差异具有统计学意义(P<0.05)。治疗后,两组的胃泌素、白细胞介素-6(IL-6)、降钙素基因相关肽(CGRP)水平均降低,胃动素、瘦素、神经肽S受体1(NPSR1)水平均升高,且观察组优于对照组,差异具有统计学意义(P<0.05)。观察组的不良反应总发生率为4.17%,低于对照组的18.75%,差异具有统计学意义(P<0.05)。结论复方阿嗪米特联合莫沙必利治疗老年消化不良患者的效果显著,可减轻临床症状,改善胃肠功能,降低不良反应发生率,值得临床推广和应用。Objective To investigate the efficacy and safety of compound azintamide combined with mosapride in the treatment of elderly patients with dyspepsia.Methods A total of 96 elderly patients with dyspepsia admitted from January to December 2020 were selected as the research objects and divided into control group and observation group by random number table method,with 48 cases in each group.The control group was treated with mosapride,and the observation group was treated with compound azintamide on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the nausea and vomiting,loss of appetite,acid regurgitation and belching,abdominal pain and bloating scores and total score in the two groups decreased,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 97.92%,which was higher than 83.33%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of gastrin,interleukin-6(IL-6)and calcitonin gene-related peptide(CGRP)in the two groups decreased,while the levels of motilin,leptin and neuropeptide S receptor 1(NPSR1)increased,those in the observation group were better than the control group,and the differences were statistically significan(P<0.05).The total incidence of adverse reactions in the observation group was 4.17%,which was lower than 18.75%in the control group,and the difference was statistically significant(P<0.05).Conclusion Compound azintamide combined with mosapride in the treatment of elderly patients with dyspepsia has significant effect,it can reduce the clinical symptoms,improve the gastrointestinal function and decrease the incidence of adverse reactions,which can be popularized and applied in clinical practice.

关 键 词：复方阿嗪米特 莫沙必利 老年患者 消化不良 胃泌素 

分 类 号：R57[医药卫生—消化系统]